Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive
License Agreement
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering
and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced
that, as contemplated in the April 18, 2016 License and Transfer Agreement (the “License Agreement”), it has received a $750,000
license maintenance fee from and entered into a Definitive License and Transfer Agreement (the “Definitive Agreement”) with Pieris
Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, “Pieris”) to continue Pieris’ license to Enumeral’s 388D4
anti-PD-1 antibody.
The Definitive Agreement continues the royalty-bearing worldwide license Enumeral has granted Pieris under specified Enumeral
patent rights and know-how to research, develop and market fusion proteins that comprise a moiety derived from Enumeral’s 388D4
anti-PD-1 antibody linked to one or more Pieris Anticalin® proteins for use in the field of oncology.
The Definitive Agreement also expands the scope of Pieris’ option to license additional Enumeral antibodies for specified
purposes. Under the Definitive Agreement, Enumeral has granted Pieris an option until May 31, 2017 to license specified Enumeral
patent rights and know-how covering two additional undisclosed Enumeral antibody programs to research, develop, and market fusion
proteins that comprise moieties derived from Enumeral antibodies linked to one or more Pieris Anticalin proteins for use in the
field of oncology, on the same terms and conditions as for Enumeral’s 388D4 anti-PD-1 antibody (each, a “Subsequent Option”).
Pieris will pay Enumeral additional undisclosed license fees in the event that Pieris exercises one or both Subsequent Options.
The sales and milestone payments and royalty provisions set forth in the Definitive Agreement remain the same as those set forth
in the License Agreement. In the event that Pieris licenses one or both of the additional antibodies pursuant to a Subsequent
Option, any resulting fusion protein products will be subject to additional royalties and development and sales milestones in the
same amounts applicable to the fusion proteins linking the licensed PD-1 antibody and one or more Anticalin proteins.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system
fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial
targets including PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents, Enumeral’s researchers apply a proprietary
immune profiling technology platform that measures functioning of the human immune system at the level of individual cells,
providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.
About Pieris
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target
validated disease pathways in a unique and transformative way. Pieris’ pipeline includes immuno-oncology multi-specifics
tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to
treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by
partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more
information, visit www.pieris.com.
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform
Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral”) with respect to
future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, Enumeral’s
stock price, services, products and licenses. No assurances can be given regarding the achievement of future results, and although
Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual
results may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that
may cause actual results, performance or achievements, or industry results to differ materially from those contemplated by such
forward-looking statements include, among others, the risks that (a) Enumeral’s expectations regarding market acceptance of the
Company’s business in general and the Company’s ability to penetrate the antibody discovery and development fields in particular,
as well as the timing of such acceptance, (b) Enumeral’s ability to attract and retain management with experience in biotechnology
and antibody discovery and similar emerging technologies, (c) the scope, validity and enforceability of Enumeral’s and third party
intellectual property rights, (d) Enumeral’s ability to raise capital when needed and on acceptable terms and conditions, (e)
Enumeral’s ability to comply with governmental regulation, (f) the intensity of competition, (g) changes in the political and
regulatory environment and in business and fiscal conditions in the United States and overseas and (h) general economic
conditions.
More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements,
including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange
Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at
http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any
obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.
Enumeral Biomedical Holdings, Inc.
Kevin Sarney, (617) 945-9146
kevin@enumeral.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160606005240/en/